MedTrace Logo

Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain

NCT00992576 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2012-02-15

No results posted yet for this study

Summary

The purpose of this study is to establish an optimal hydromorphone - naloxone ratio with an improved bowel function for constipated pain patients.

Conditions

Interventions

DRUG

Active Hydromorphone PR + Active Naloxone PR

Optimal pain relief and improved bowel function in constipated pain patients

DRUG

Active Hydromorphone PR + Placebo Naloxone PR

Optimal pain relief and improved bowel function in constipated pain patients

Sponsors & Collaborators

  • Mundipharma Research GmbH & Co KG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-11-30
Completion
2012-01-31

Countries

  • Australia
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Israel
  • Netherlands
  • Poland
  • Romania
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00992576 on ClinicalTrials.gov